torsemide Side Effects
Also known as: Demadex
Analysis of 31,122 adverse event reports submitted to the FDA from 2004 to 2025.
Total Reports
31,122
Death-Related
4,265
13.7% of reports
Hospitalizations
16,889
54.3% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 4,265 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 1,637 |
| DYSPNOEA | 389 |
| RENAL FAILURE | 307 |
| CARDIAC FAILURE | 292 |
| PNEUMONIA | 285 |
| ACUTE KIDNEY INJURY | 261 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 225 |
| SEPSIS | 221 |
| CARDIAC FAILURE CONGESTIVE | 205 |
| DIARRHOEA | 196 |
| CARDIAC ARREST | 187 |
| CHRONIC KIDNEY DISEASE | 187 |
| RESPIRATORY FAILURE | 181 |
| HYPOTENSION | 178 |
| FALL | 176 |
| ASTHENIA | 167 |
| ANAEMIA | 166 |
| FATIGUE | 158 |
| NAUSEA | 155 |
| VOMITING | 139 |
Reactions in Hospitalization Reports
Top reactions in 16,889 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| DYSPNOEA | 2,439 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 1,463 |
| ACUTE KIDNEY INJURY | 1,290 |
| FALL | 1,240 |
| ANAEMIA | 1,209 |
| OEDEMA PERIPHERAL | 1,168 |
| NAUSEA | 1,159 |
| DIARRHOEA | 1,129 |
| DIZZINESS | 1,100 |
| PNEUMONIA | 1,094 |
| FATIGUE | 1,084 |
| CARDIAC FAILURE | 1,043 |
| HYPOTENSION | 1,004 |
| ATRIAL FIBRILLATION | 918 |
| VOMITING | 853 |
| ASTHENIA | 803 |
| CONDITION AGGRAVATED | 762 |
| PYREXIA | 747 |
| DEHYDRATION | 722 |
| RENAL IMPAIRMENT | 696 |
Nearby — Related Medications
What the FAERS Data Reveals About torsemide Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 31,122 voluntary reports linked to torsemide and its brand equivalents (Demadex), spanning 2004 through 2025. Of those, 4,265 (13.7%) listed death as an outcome and 16,889 (54.3%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 53% were female and 46% male; age distribution skews toward 75+, with 9,149 reports in that bracket. The single most reported reaction is dyspnoea with 3,305 submissions, followed by fatigue and nausea.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.